TITLE

Cardioprotective effects of ACE inhibitors in African American men

PUB. DATE
December 2009
SOURCE
Internal Medicine Alert;12/29/2009, Vol. 31 Issue 24, p192
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on a study conducted in Washington, District of Columbia on the efficacy of angiotensin converting enzyme (ACE) inhibitors to treat Coronary Artery Disease (CAD), Cardiovascular Disease (CVD), and diabetes as well as to prevent cardiovascular risks in African American men.
ACCESSION #
47507399

 

Related Articles

  • Cardiac groups revise angina management guidelines. K.T. // American Journal of Health-System Pharmacy;1/1/2003, Vol. 60 Issue 1, p12 

    Reports on the revised guidelines for the management of chronic stable angina call for the widespread use of angiotensin-converting-enzyme (ACE) inhibitors in patients with cardiovascular disease in the U.S. Details on patients receiving ACE inhibitors; Provisions of the revised guidelines on...

  • Beta-blockers and ACE inhibitors: New data, old myths. Pinkowish, Mary Desmond; Francis, Gary S. // Patient Care;7/15/2000, Vol. 34 Issue 13, p62 

    Presents an update on the cardiovascular applications of angiotensin converting enzyme inhibitors and beta-blockers. Appropriate dosages; Adverse reactions; Beta-blockers after surgery; Misunderstandings about the use of beta-blockers in patients with respiratory disease. INSETS: Selected...

  • Differences Among ACE Inhibitors. Kostis, John B. // American Journal of Hypertension;Nov2010, Vol. 23 Issue 11, p1156 

    The article discusses the differences among angiotensin-converting enzyme inhibitors (ACEIs), which are commonly used in treating cardiovascular disease. It states that ACEIs may differ in their chemical classes, pharmacokinetics and the ligand to ACE. It also cites the findings of the study...

  • The Role of Older Pharmacological Therapies in Cardiovascular Disease. Black, Henry; Cushman, William; Frishman, William; Sica, Domenic // Medical Roundtable: Cardiovascular Edition;Spring2011, Vol. 2 Issue 2, p82 

    The discussion focused primarily on: (1) The comparison of efficacy, cost and side effect profiles of the older cardiovascular drugs versus the newer compounds, (2) the use of beta blockers, diuretics, calcium channel blockers, anticoagulants, aldosterone receptor antagonists, angiotensin...

  • Managing Hyperkalemia Caused by Inhibitors of the Renin—Angiotensin—Aldosterone System. Palmer, Biff F. // New England Journal of Medicine;8/5/2004, Vol. 351 Issue 6, p585 

    The article discusses the managing of hyperkalemia caused by angiotensin converting enzyme (ACE) inhibitors and angiotensin-receptor blockers. It is reported that the patients who are at the greatest risk of complication with hyperkalemia are the same cardiovascular patients who derive the...

  • Technology for the Production and Utilization of Food Protein-Derived Anti-hypertensive Peptides: A Review. Aluko, Rotimi E. // Recent Patents on Biotechnology;Nov2007, Vol. 1 Issue 3, p260 

    Angiotensin converting enzyme (ACE)-inhibitory drugs have been used as therapeutic tools in the clinical management of hypertension and associated cardiovascular disorders. Food-derived ACE-inhibitory peptides have lower potency than similar acting drugs but the peptides usually have no adverse...

  • Angiotensin-Converting Enzyme 2 – A New Cardiac Regulator. Boehm, Manfred; Nabel, Elizabeth G. // New England Journal of Medicine;11/28/2002, Vol. 347 Issue 22, p1795 

    The article discusses the role of Angiotensin-Converting Enzyme (ACE) inhibitors in the treatment of heart diseases. In the pathway of the renin angiotensin system, renin is secreted from the juxtaglomerular apparatus of the kidney and acts on the circulating precursor angiotensinogen to...

  • The ACE Insertion/Deletion Polymorphism and Risk of Cancer, a Review and Meta-Analysis of the Literature. Ruiter, R.; Visser, L. E.; Van Duijn, C. M.; Stricker, B. H. Ch. // Current Cancer Drug Targets;May2011, Vol. 11 Issue 4, p421 

    No abstract available.

  • Diuretic led to fewer adverse events in patients with metabolic syndrome. Haigh, Christen; Messerli, Franz H. // Cardiology Today;Apr2008, Vol. 11 Issue 4, p18 

    The article reports that thiazide-type diuretics are safer and more effective in preventing cardiovascular or renal events than calcium antagonists, alpha-blockers and angiotensin-converting enzyme inhibitors. This was confirmed by the Antihypertensive and Lipid-Lowering Treatment to Prevent...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics